小剂量低分子肝素改善老年重症肺炎预后:1 173例患者的Meta分析
该Meta分析纳入14项RCT共1 173例老年重症肺炎患者(低分子肝素组590例,常规治疗组583例),比较常规治疗(改善通气、抗感染、祛痰、平喘、维持内环境)与加用低分子肝素4000 U皮下注射每日1次连用7天的疗效。结果显示低分子肝素组治疗7天后氧合指数升高(MD=19.25,95%CI 16.88~21.61)、机械通气时间缩短(MD=-48.88,95%CI -67.42~-30.33)、住院病死率降低(OR=0.40,95%CI 0.22~0.73)、APACHE II评分降低(MD=-3.38,95%CI -3.94~-2.83)、ICU住院时间缩短(MD=-4.51,95%CI -5.75~-3.27)。两组7天凝血指标变化及出血发生率无显著差异。作者认为小剂量低分子肝素可改善老年重症肺炎预后且对凝血功能无明显副作用。
要点
- 老年重症肺炎患者在常规治疗基础上加用低分子肝素4000 U皮下注射每日1次连用7天,住院病死率降低(OR=0.40,95%CI 0.22~0.73,P=0.003)。
- 该方案治疗7天后氧合指数升高(MD=19.25,95%CI 16.88~21.61),机械通气时间缩短(MD=-48.88,95%CI -67.42~-30.33)。
- 该方案治疗7天后APACHE II评分降低(MD=-3.38,95%CI -3.94~-2.83),ICU住院时间缩短(MD=-4.51,95%CI -5.75~-3.27)。
- 两组7天凝血酶时间、凝血酶原时间、纤维蛋白原变化及出血发生率无显著差异(出血OR=0.86,95%CI 0.36~2.07,P=0.74)。
- 漏斗图分析显示纳入的10项关于治疗7天后APACHE II评分的研究存在发表偏倚。
适用人群与场景
- 老年重症肺炎患者,纳入14项随机对照试验共1 173例,其中低分子肝素组590例、常规治疗组583例。
处置流程与药物剂量
- 常规治疗组采用改善通气、抗感染、祛痰、平喘、维持内环境等治疗。
- 低分子肝素组在常规治疗基础上皮下注射低分子肝素4000 U,每日1次,连用7天。
研究设计与关键结果
- 研究类型为Meta分析,纳入14项随机对照试验,共1 173例老年重症肺炎患者,低分子肝素组590例、常规治疗组583例。
- 与常规治疗相比,低分子肝素组治疗7天后氧合指数升高(MD=19.25,95%CI 16.88~21.61,P<0.000 01)。
- 低分子肝素组机械通气时间缩短(MD=-48.88,95%CI -67.42~-30.33,P<0.000 01)。
- 低分子肝素组住院病死率降低(OR=0.40,95%CI 0.22~0.73,P=0.003)。
- 低分子肝素组治疗7天后APACHE II评分降低(MD=-3.38,95%CI -3.94~-2.83,P<0.000 01)。
- 低分子肝素组ICU住院时间缩短(MD=-4.51,95%CI -5.75~-3.27,P<0.000 01)。
- 两组7天凝血指标变化无显著差异:凝血酶时间MD=0.57(95%CI -0.15~1.28,P=0.12)、凝血酶原时间MD=0.32(95%CI -0.35~0.98,P=0.35)、纤维蛋白原MD=-0.17(95%CI -0.45~0.10,P=0.22);出血发生率OR=0.86(95%CI 0.36~2.07,P=0.74)。
- 漏斗图分析显示纳入的10项关于治疗7天后APACHE II评分的研究存在发表偏倚。
证据类型、等级与局限
- 证据类型为随机对照试验的Meta分析;原文称纳入研究设计良好、质量高。
- 局限:漏斗图分析显示纳入的10项关于治疗7天后APACHE II评分的研究存在发表偏倚。
对床旁实践的改变
- 作者认为小剂量低分子肝素可改善老年重症肺炎预后,且对凝血功能无明显副作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the effect of small dose of low molecular weight heparin on the prognosis of elderly patients with severe pneumonia using systematic evaluation method.
METHODS: Databases including Wanfang data, VIP, CNKI, SinoMed, PubMed, Embase and Cochrane Library were searched for randomized controlled trial (RCT) studies about the comparison of conventional therapy and low molecular weight heparin on prognosis of elderly patients with severe pneumonia from the time of database establishment to August 2019. The patients in conventional treatment group were treated by improving ventilation, anti-infection, eliminating phlegm, relieving asthma and maintaining homeostasis while those in low molecular weight heparin group were subcutaneously injected with low molecular weight heparin of 4 000 U, once a day for 7 days. The patients' main outcomes included the oxygenation index (PaO2/FiO2) after 7 days of treatment, duration of mechanical ventilation, mortality in hospital, and secondary outcomes included acute physiology and chronic health evaluation II (APACHE II) score and coagulation function after 7 days of treatment, the length of intensive care unit (ICU) stay, and incidence of bleeding. Data extraction and quality evaluation were conducted. The Meta-analysis of included studies that met the quality standards was performed using RevMan 5.3 software. Funnel diagram analysis was used to analyze the parameters with no less than 10 studies enrolled.
RESULTS: A total of 14 RCT studies were enrolled involving 1 173 elderly patients with severe pneumonia, among whom 590 received low molecular weight heparin while the other 583 received conventional therapy. All the included studies were well designed and of high quality. The results of Meta-analysis showed that compared with conventional therapy, small dose of low molecular weight heparin significantly elevated PaO2/FiO2 after 7 days of treatment [mean difference (MD) = 19.25, 95% confidence interval (95%CI) was 16.88 to 21.61, P < 0.000 01], shortened the duration of mechanical ventilation (MD = -48.88, 95%CI was -67.42 to -30.33, P < 0.000 01), and decreased mortality in hospital [odds ratio (OR) = 0.40, 95%CI was 0.22 to 0.73, P = 0.003] and APACHE II score after 7 days of treatment (MD = -3.38, 95%CI was -3.94 to -2.83, P < 0.000 01), and shortened the length of ICU stay (MD = -4.51, 95%CI was -5.75 to -3.27, P < 0.000 01). There was no significant difference in the changes of coagulation parameters after 7 days of treatment or the incidence of bleeding between low molecular weight heparin group and conventional therapy group [7-day thrombin time (TT): MD = 0.57, 95%CI was -0.15 to 1.28, P = 0.12; 7-day prothrombin time (PT): MD = 0.32, 95%CI was -0.35 to 0.98, P = 0.35; 7-day fibrinogen (FIB): MD = -0.17, 95%CI was -0.45 to 0.10, P = 0.22; incidence of bleeding: OR = 0.86, 95%CI was 0.36 to 2.07, P = 0.74]. The funnel diagram showed that there was publication bias of included 10 studies about APACHE II score after 7 days of treatment.
CONCLUSIONS: Small dose of low molecular weight heparin can improve the prognosis of elderly patients with severe pneumonia and it has no obvious side-effect on coagulation function.
参考来源
- Yang H, Qian H, Shen F, et al. [Small dose of low molecular weight heparin improves the prognosis of elderly patients with severe pneumonia: a Meta-analysis of 1 173 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32148227. doi:10.3760/cma.j.cn121430-20191008-00005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。